Ozempic for Kidney Disease: What the FLOW Trial Showed

On January 28, 2025, the FDA approved a new use for Ozempic (semaglutide): reducing the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults who have type 2 diabetes and chronic kidney disease (CKD). That made semaglutide the first GLP-1 receptor agonist ever approved to protect the kidneys¹ — a genuinely significant moment in kidney medicine. But it is also one of the easiest GLP-1 headlines to misread. The approval is narrow and specific, and the gap between what it actually says and how it gets repeated online is wide. This guide walks through exactly what the FLOW trial found, who the benefit applies to, why it probably works, and — just as important — where the evidence stops. It is general education, not medical advice for your situation.

The single most important sentence up front: this is an indication for people who have both type 2 diabetes and chronic kidney disease. It is not a kidney-protection approval for weight-loss users, and it is not an approval for kidney disease in people without diabetes. We'll come back to why that distinction is the whole story.

A grounding fact, too. Ozempic and Wegovy are the same molecule — semaglutide — sold under two brand names for two different approved uses (diabetes for Ozempic, chronic weight management for Wegovy). We unpack that in Ozempic vs Wegovy: same drug, different label. The kidney indication sits on the Ozempic (diabetes) side, at the 1.0 mg weekly dose — not the higher Wegovy weight-loss dose.

The FLOW trial: what it actually showed

The approval rests on one landmark study: FLOW (Evaluate Renal Function with Semaglutide Once Weekly), published in the New England Journal of Medicine in 2024. It was a randomized, double-blind, placebo-controlled trial that enrolled 3,533 adults who shared two defining features: they had type 2 diabetes, and they had chronic kidney disease (reduced kidney function with albuminuria). Participants were randomized to once-weekly semaglutide 1.0 mg or placebo, on top of standard kidney and diabetes care, and followed for a median of more than three years².

The headline result: semaglutide reduced the risk of the primary composite kidney outcome — onset of kidney failure (dialysis, transplant, or an eGFR below 15), at least a 50% loss of kidney function, or death from kidney-related or cardiovascular causes — by 24% versus placebo (hazard ratio 0.76)². The benefit was strong and consistent enough that the trial was stopped early for efficacy — the independent monitoring board concluded the drug was clearly working and it would be unethical to keep people on placebo.

The kidney result wasn't the only win. Two secondary outcomes mattered enormously for how the approval was worded:

• •Death from cardiovascular causes fell by 29% (hazard ratio 0.71)².
• •Death from any cause fell by 20% (hazard ratio 0.80)².

Those are hard endpoints — not lab surrogates, but people who didn't progress to dialysis and people who didn't die. That combination of slowing kidney decline and reducing cardiovascular death is exactly what earned semaglutide its place in the label.

What the FDA actually approved (and the exact population)

In January 2025, the FDA translated FLOW into an indication, and the precision of the wording is the whole point. Ozempic is now indicated to reduce the risk of sustained kidney function decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease¹. Novo Nordisk's own framing is careful: semaglutide is the first and only GLP-1 receptor agonist approved for this use¹.

Read the qualifiers, because they are not boilerplate. The approved population is people who have type 2 diabetes AND chronic kidney disease — the exact group FLOW enrolled. The indication does not say "semaglutide protects everyone's kidneys," and it does not extend to:

• •People taking Wegovy or Ozempic for weight loss who have healthy kidneys.
• •People with chronic kidney disease but without type 2 diabetes.
• •People with diabetes but without established kidney disease (FLOW required existing CKD to enroll).

This is the single most common way the FLOW story gets distorted: a benefit proven in diabetic kidney disease gets quietly generalized into "Ozempic is good for your kidneys" — full stop. The trial does not license that leap. The honest version is narrower and, frankly, still remarkable.

Why does it work? More than just blood sugar

A fair question: is the kidney benefit just because semaglutide lowers blood sugar and weight, which are both bad for kidneys? Better glucose control and weight loss certainly help, and some of the benefit surely flows through them. But the evidence suggests that's not the whole story.

An earlier exploratory mediation analysis of semaglutide and liraglutide found these drugs appeared to slow kidney-function decline through effects only partly explained by changes in blood sugar, blood pressure, or body weight³ — hinting at more direct effects on the kidney. Mechanistically, GLP-1 receptor agonists appear to reduce inflammation and oxidative stress in the kidney, ease the pressure inside the filtering units (glomeruli), and reduce albuminuria — effects that plausibly protect kidney tissue beyond what glucose-lowering alone would do.

A follow-on FLOW analysis added another reassuring detail: the cardiovascular and kidney benefits held across the spectrum of CKD severity, including in people with more advanced kidney disease⁴ — meaning the benefit wasn't confined to the mildest cases. The honest summary: the kidney protection is real and partly independent of blood sugar and weight — but the exact mechanistic contribution of each pathway is still being worked out.

How this fits the wider semaglutide evidence

FLOW didn't appear out of nowhere. It's the kidney chapter of a broader cardio-renal-metabolic story that semaglutide has been building, one dedicated trial at a time:

• •In SUSTAIN-6 (2016), semaglutide at diabetes doses cut major cardiovascular events by 26% in people with type 2 diabetes at high cardiovascular risk — the basis of Ozempic's earlier cardiovascular indication⁵.
• •In SELECT (2023), semaglutide 2.4 mg (the Wegovy dose) cut major cardiovascular events by 20% in people with obesity and established heart disease but without diabetes — a different population entirely. We cover that in do Wegovy & Ozempic protect the heart?⁶.
• •And now FLOW (2024) adds the kidney indication.

The pattern is consistent and worth internalizing: each indication stands on its own trial, in its own population. Heart protection in obesity-without-diabetes (SELECT) doesn't automatically transfer to kidneys; kidney protection in diabetes-with-CKD (FLOW) doesn't automatically transfer to healthy-kidney weight-loss users. That discipline is what separates honest reporting from hype.

It's also worth pairing this long-term protective story with the short-term kidney caution, because they coexist. Semaglutide's most common side effects are gastrointestinal, and severe nausea, vomiting, or diarrhea can cause dehydration, which can in turn cause acute kidney injury — a labeled risk that's separate from, and not contradicted by, the long-term protection. We cover both sides in detail in semaglutide and your gallbladder & kidneys. The two-sided takeaway: stay hydrated and report severe GI symptoms in the short term; the long-term kidney protection is a distinct, population-specific finding.

What this does — and doesn't — mean for you

Here is the honest bottom line, separated into what the evidence supports and where it stops.

What's proven: In adults with type 2 diabetes and chronic kidney disease, once-weekly semaglutide 1.0 mg (Ozempic) reduces the risk of kidney disease worsening, kidney failure, and cardiovascular death — a 24% reduction in the composite kidney outcome, a 29% reduction in cardiovascular death, and a 20% reduction in death from any cause, in a randomized trial stopped early for benefit². This is now an FDA-approved indication¹.

What's not proven: That semaglutide protects the kidneys of someone taking Wegovy purely for weight loss with healthy kidneys (FLOW didn't study them). That it protects the kidneys of someone with CKD but no diabetes (also not studied). That compounded semaglutide — which was never the molecule studied in FLOW — delivers the same kidney outcome. The trial efficacy applies to the FDA-approved branded product, at the studied dose, in the studied population.

The framing that matters: This is a prescription-only medicine with real benefits and real risks. The kidney indication makes it a serious therapeutic tool for the right person — someone with type 2 diabetes and chronic kidney disease, whose clinician is weighing it against the rest of their picture — not a reason to treat semaglutide as a kidney supplement for everyone. Whether you fit the FLOW population, and whether the benefit outweighs the risks for you, is a conversation for your clinician.

The kidney is not the only organ where semaglutide earned a brand-new indication on its own dedicated trial — in 2025 it also became the first GLP-1 approved for fatty-liver disease; see Wegovy for MASH (fatty liver): the new FDA approval, and for the heart side, do Wegovy & Ozempic protect the heart?. For the complete picture of how semaglutide works, what results to expect, and the full safety profile, start with our pillar guide, Semaglutide: how it works, results & side effects. And if you're weighing providers, our editorial ranking is at the best semaglutide options, rated.